Effect of ketamine on endogenous pain modulation in healthy volunteers.
Inhibitory and facilitatory descending pathways, originating at higher central nervous system sites, modulate activity of dorsal horn nociceptive neurons, and thereby influence pain perception. Dysfunction of inhibitory pain pathways or a shift in the balance between pain facilitation and pain inhibition has been associated with the development of chronic pain. The N-methyl-d-aspartate receptor antagonist ketamine has a prolonged analgesic effect in chronic pain patients. This effect is due to desensitization of sensitized N-methyl-d-aspartate receptors. Additionally, ketamine may modulate or enhance endogenous inhibitory control of pain perception. Diffuse noxious inhibitory control (DNIC) and offset analgesia (OA) are 2 mechanisms involved in descending inhibition. The present study investigates the effect of a ketamine infusion on subsequent DNIC and OA responses to determine whether ketamine has an influence on descending pain control. Ten healthy subjects (4 men/6 women) received a 1-hour placebo or S(+)-ketamine (40mg per 70kg) infusion on 2 separate occasions in random order. Upon the termination of the infusion, DNIC and OA responses were obtained. After placebo treatment, significant descending inhibition of pain responses was present for DNIC and OA. In contrast, after ketamine infusion, no DNIC was observed, but rather a significant facilitatory pain response (P<0.01); the OA response remained unchanged. These findings suggest that the balance between pain inhibition and pain facilitation was shifted by ketamine towards pain facilitation. The absence of an effect of ketamine on OA indicates differences in the mechanisms and neurotransmitter influences between OA and DNIC. Diffuse noxious inhibitory control responses following a 1-hour low-dose ketamine treatment displayed facilitation of pain in response to experimental noxious thermal stimulation.
Department of Anesthesiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands Comprehensive Center for Pain Research, University of Florida College of Dentistry, Gainesville, FL, USA.
Marieke
M
Niesters
Albert
A
Dahan
Maarten
M
Swartjes
Ingeborg
I
Noppers
Roger B
RB
Fillingim
Leon
L
Aarts
Elise Y
EY
Sarton
D000328:Adult; D000368:Aged; D000778:Anesthetics, Dissociative / Q000008:administration & dosage*; D019540:Area Under Curve; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement / Q000379:methods; D058748:Pain Perception / Q000187:drug effects* / Q000502:physiology; D016037:Single-Blind Method; D013997:Time Factors; D055815:Young Adult
D000778:Anesthetics, Dissociative; D007649:Ketamine
Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010;13:245-249.
Bell R, Eckleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003;(1):CD003351.
Goffaux P, Redmond WJ, Rainville P, Marchand S. Descending analgesia—when the spine echoes what the brain expects. Pain. 2007;130:137-143.
Grill JD, Coghill RC. Transient analgesia evoked by noxious stimulus offset. J Neurophysiol. 2002;87:2205-2208.
Guan Y, Tereyama R, Dubner R, Ren K. Plasticity in excitatory amino acid receptor-mediated descending pain modulation and inflammation. J Pharmacol Exp Ther. 2002;300:513-520.
King CD, Wong F, Currie T, Mauderli AP, Fillingim RB, Riley JL 3rd. Deficiency in endogenous modulation of prolonged heat pain in patients with irritable bowel syndrome and temporomandibular disorder. Pain. 2009;143:172-178.
Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13:189-196.
Le Bars D, Villanueva L, Bouhassira D, Willer JC. Diffuse noxious inhibitory controls (DNIC) in animals and in man. Path Physiol Exp Ther. 1992;4:55-65.
Le Bars D, Willer JC, De Broucker T. Morphine blocks descending inhibitory controls in humans. Pain. 1992;48:13-20.
Lipa SM, Kavaliers M. Sex differences in the inhibitory effects of the NMDA antagonist, MK-801, on morphine and stress-induced analgesia. Brain Res Bull. 1990;24:627-630.
Lomas LM, Terner JM, Picker MJ. Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: Comparison to two models of acute pain. Pharmacol Biochem Behav. 2008;89:127-136.
Lutfy K, Hurlbut DE, Weber E. Blockade of morphine-induced analgesia and tolerance by MK-801. Brain Res. 1993;616:83-88.
Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000;20:246-252.
Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355-474.
Mitchell AC. Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliat Med. 1999;13:427-428.
Moont R, Pud D, Sprecher E, Sharvit G, Yarnitsky D. ‘Pain inhibits pain’ mechanisms: is pain modulation simply due to distraction? Pain. 2010;150:113-120.
Nemmani KVS, Grisel JE, Stowe JR, Smith-Carliss R, Mogil JS. Modulation of morphine analgesia by site-specific N-methyl-d-aspartate receptor antagonists: dependence on sex, site of antagonism, morphine dose, and time. Pain. 2004;109:274-283.
Nesher N, Serovian I, Marouani N, Chazan S, Weinbroum AA. Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. Pharmacol Res. 2008;58:38-44.
Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-d-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108-1116.
Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse noxious inhibitory control (DNIC)-like effect in humans. Pain. 2009;144:16-19.
Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain—new perspective of opioid-induced hyperalgesia. Pain. 2009;139:431-438.
Roberts J, Ossipov MH, Porreca F. Glial activation in the rostroventromedial medulla promotes descending facilitation to mediate inflammatory hypersensitivity. Eur J Neurosci. 2009;30:229-241.
Sarton E, Teppema LJ, Olievier CN, Nieuwenhuijs D, Matthes HWD, Kieffer BL, Dahan A. The involvement of the μ-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg. 2001;93:1495-1500.
Schmidt AP, Tort AB, Silveira PP, Böhmer AE, Hansel G, Knorr L, Schallenberger C, Dalmaz C, Elisabetsky E, Crestana RH, Lara DR, Souza DO. The NMDA antagonist MK-801 induces hyperalgesia and increases CSF excitatory amino acids in rats: reversal by guanosine. Pharmacol Biochem Behav. 2009;91:549-553.
Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147:107-115.
Seifert F, Kiefer G, deCol R, Schmelz M, Maihöfer C. Differential endogenous pain modulation in complex-regional pain syndrome. Brain. 2009;132:788-800.
Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E, Olofsen E. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology. 2009;111:892-903.
Sigtermans M, Noppers I, Sarton E, Bauer M, Mooren R, Olofsen E, Dahan A. An observational study on the effect of S(+)-ketamine on chronic versus experimental acute pain in complex regional pain syndrome type 1 patients. Eur J Pain. 2010;14:302-307.
Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145:304-311.
Sörensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia—are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol. 1997;24:1615-1621.
Talbot JD, Duncan GH, Bushnell MC, Boyer M. Diffuse Noxious Inhibitory Controls (DNICs): psychophysical evidence in man for intersegmental suppression of noxious heat perception by cold pressor pain. Pain. 1987;30:221-232.
Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Rev. 2004;46:295-309.
van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a model of endogenous modulation in clinical pain syndromes. J Pain. 2010;11:408-419.
Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines pain enhancement. Neurosignals. 2005;14:166-174.
Yelle MD, Oshiro Y, Kraft RA, Coghill RC. Temporal filtering of nociceptive information by dynamic activation of endogenous pain modulatory systems. J Neurosci. 2009;29:10264-10271.
Yelle MD, Rogers JM, Coghill RC. Offset analgesia: a temporal contrast mechanism for nociceptive information. Pain. 2008;134:174-186.